GlycoT develops chemoenzymatic glycan‑remodeling technologies that enable site‑specific conjugation of antibodies for therapeutic and diagnostic applications. Their transglycosylation platform is licensed to partners such as Genovis and Daiichi Sankyo, allowing the creation of customized antibody‑drug conjugates and research reagents with precise glycan modifications.
Funding
Funding not disclosed
Founders
Product
Problem
Developing antibody‑drug conjugates and diagnostic antibodies requires precise, site‑specific attachment of payloads while maintaining antibody stability and function. Conventional chemical conjugation methods often produce heterogeneous products, leading to variable efficacy and safety profiles.
Solution
GlycoT provides a chemoenzymatic glycan‑remodeling platform that combines engineered transglycosylation enzymes with scalable synthetic chemistry to remodel antibody Fc glycans. The approach enables the selective installation of defined glycan handles, which serve as anchors for payloads such as drugs, imaging agents, or targeting ligands. By preserving the native antibody structure and achieving homogeneous conjugates, the technology improves batch consistency, pharmacokinetics, and therapeutic index. GlycoT’s platform is licensed to major pharmaceutical partners and supported by SBIR funding, facilitating integration into existing antibody development pipelines for both therapeutic and diagnostic applications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing antibody‑based therapeutics or diagnostics that require site‑specific conjugation, as well as research organizations seeking robust glycoengineering tools.
Features
- Enzyme‑driven transglycosylation that remodels native Fc glycans to introduce defined reactive sites
- One‑step chemoenzymatic conjugation workflow compatible with standard antibody manufacturing processes
- Ability to attach diverse payloads (small molecules, polymers, ligands) while retaining antigen‑binding activity
- Production of homogeneous antibody‑drug conjugates with controlled drug‑to‑antibody ratios
- Scalable chemistry and enzyme engineering that support manufacturing at commercial volumes